TRDA Entrada Therapeutics PE ratio, current and historical analysis
As at Apr 2, 2025, the TRDA stock has a PE ratio of 5.0. This is based on the current EPS of $1.76 and the stock price of $8.8 per share. A decrease of 55% has been recorded in the PE ratio compared to the average of 11.1 of the past four quarters.
TRDA PE ratio history
The mean historical PE ratio of Entrada Therapeutics over the last three years is 7.99. The current 5.0 price-to-earnings ratio is 37% less than the historical average. In the past three years, TRDA's PE ratio reached its highest point in the Mar 2024 quarter at 20.24, with a price of $14.17 and an EPS of $0.7. The Sep 2022 quarter saw the lowest point at 1.14, with a price of $15.76 and an EPS of $13.79.
Entrada Therapeutics PE ratio by year
| Year | PE ratio | PE change | Price | EPS |
|---|---|---|---|---|
| 2024 | 9.82 | N/A | $17.29 | $1.76 |
| 2023 | N/A | N/A | $15.09 | -$0.2 |
| 2022 | N/A | N/A | $13.52 | -$3.02 |
| 2021 | N/A | N/A | $17.12 | -$8.16 |
| 2020 | N/A | N/A | N/A | -$24 |
| 2019 | N/A | N/A | N/A | -$0.76 |
Entrada Therapeutics PE ratio by quarter (TTM)
| Year | PE ratio | PE change | Price | EPS |
|---|---|---|---|---|
| Dec 2024 | 9.82 | 2.61% | $17.29 | $1.76 |
| Sep 2024 | 9.57 | 107.59% | $15.98 | $1.67 |
| Jun 2024 | 4.61 | -77.22% | $14.25 | $3.09 |
| Mar 2024 | 20.24 | N/A | $14.17 | $0.7 |
| Dec 2023 | N/A | N/A | $15.09 | -$0.2 |
| Sep 2023 | N/A | N/A | $15.8 | -$0.7 |
| Jun 2023 | N/A | N/A | $15.14 | -$2.57 |
| Mar 2023 | N/A | N/A | $14.5 | -$2.53 |
| Dec 2022 | N/A | N/A | $13.52 | -$3.02 |
| Sep 2022 | 1.14 | -54.94% | $15.76 | $13.79 |
| Jun 2022 | 2.53 | N/A | $12.18 | $4.81 |
| Mar 2022 | N/A | N/A | $9.39 | -$2.01 |
| Dec 2021 | N/A | N/A | $17.12 | -$8.16 |
| Sep 2021 | N/A | N/A | N/A | -$31.46 |
| Jun 2021 | N/A | N/A | N/A | -$27.81 |
TRDA average PE ratio chart
The current PE ratio of TRDA is lower than the 3-year average.
TRDA PE vs peers
TRDA's PE ratio is below its peer stocks AMGN and GILD.
| Stock name | PE ratio | Market cap |
|---|---|---|
| TRDA Entrada Therapeutics Inc | 4.66 | $308.28M |
| BIIB Biogen Inc | 11.69 | $19.19B |
| REGN Regeneron Pharmaceuticals Inc | 14.97 | $66.92B |
| AMGN Amgen Inc | 40.62 | $166.28B |
| GILD Gilead Sciences Inc | 298.97 | $141.48B |
| VRTX Vertex Pharmaceuticals Inc | N/A | $124.98B |
| NTLA Intellia Therapeutics Inc | N/A | $716.34M |
| MRNA Moderna Inc | N/A | $10.07B |
| CRSP CRISPR Therapeutics AG | N/A | $2.83B |
| EDIT Editas Medicine Inc | N/A | $93.35M |
Frequently asked questions
What is Entrada Therapeutics's PE ratio?
TRDA stock has a price to earnings ratio of 5 as of Apr 2, 2025.
What is the 3-year average PE ratio for Entrada Therapeutics (TRDA)?
As an average over the last 3 years, TRDA stock has a PE ratio of 7.99.
What is the highest PE ratio for TRDA?
In the last three years, the Mar 2024 quarter recorded the highest quarterly PE ratio at 20.24.
How does the current PE ratio for TRDA compare to its historical average?
TRDA's current price to earnings ratio is 37% below its 3-year historical average.
Why is Entrada Therapeutics's PE ratio so low?
A company with a lower PE ratio may indicate that the market has lower growth expectations for the company's future earnings.
How is TRDA's PE ratio calculated (Entrada Therapeutics PE ratio formula)?
You can calculate the P/E ratio by dividing the most recent stock price by the trailing twelve months earnings per share(EPS). As of today (Apr 2, 2025), Entrada Therapeutics's stock price is $8.8. The earnings per share for the trailing twelve months (TTM) ending Dec 2024 is $1.76. Therefore, Entrada Therapeutics's price to earnings ratio for today is 5. PE RATIO(5) = STOCK PRICE($8.8) / TTM EPS($1.76)
All PE ratio stats are based on quarterly TTM periods, unless otherwise specified. Data from 
and Sharadar.